| |||||||
Former Names B6.Cg-Tg(Ins2-NP)25-3Scr/MvhJ (Changed: 31-MAR-05 ) Type Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse Background Strain C57BL/6 Donor Strain (C57BL/6 x BALB)F2 H2 Haplotype b Donating Investigator Matthais von Herrath, La Jolla Institute for Allergy and Immun Appearance
black
Related Genotype: a/aDescription
Transgenic mice were created with the Lymphocytic choriomeningitis virus (LCMV) nucleoprotein(NP) or glycoprotein(GP) under the control of the rat insulin promoter. Northern blot analysis identifies a 3kb band expected of the transgene and SV40 processing signals in the pancreas (Oldstone et al., 1991). Ins2-NP expression was determined in the pancreas and thymus by RT-PCR (von Herrath et al 1994). Tg(Ins2-NP)25-3Olds untreated mice rarely develop insulin-dependent diabetes mellitus (IDDM). When challenged with LCMV they develop IDDM. The B6.Cg -Tg(Ins2-NP)25-3Olds mice (H2b) exhibit a slower (30-120 days) onset of IDDM than the C.Cg-Tg(Ins2-NP)25-3Olds mice (H2d) (10-21 days) or the B6.Cg -Tg(Ins2-GP) 34-20Olds mice (H2b) (10-14 days) (Oldstone et al.,1991, Homann et al.,1999). Thymic expression of nucleoprotein has been shown to be responsible for this delayed onset of IDDM. Thymi from newborn B6.Cg-Tg(Ins2-NP)25-3Olds transplanted into hosts homozygous for Prkdcscid fail to produce a primary CTL response when challenged with LCMV, although thymi transplanted from C.Cg-Tg(Ins2-NP)25-3Olds mice mount a response. CD8 T cells are required for IDDM development in both nucleoprotein and glycoprotein transgenic mice, as is interferon gamma. In interferon gamma deficient transgenicsstimulated with LCMV, CTLs were present in the pancreas and around the islets of Langerhans, but did not infiltrate the islets. Additionally, nucleoprotein transgenic animals require the presence of CD4 T cells. (von Herrath, et al, 1994 and 1997)Diabetes can be prevented in the C.B6-Tg(Ins2-NP)25-3Olds (H2d) mice after its induction by LCMV infection through oral insulin treatment and this model has proven that bystander suppression of autoaggressive CD8 T cells can occur in the pancreatic draining lymph node (Homann et al., 1999).
A single dose injection of anti CD80, anti CD86 or anti CD80/anti CD86 antibodies does not prevent LCMV induced diabetes in either the NP or GP transgenic mice. LCMV challenged GP transgenic mice are partially protected from diabetes by anti CD80 antibodies and completely protected by anti CD86 or anti CD80/CD86 antibodies injected daily for 14 days. However, LCMV challenged NP transgenic mice have accelerated diabetes onset when treated with anti CD80/CD86 antibodies injected daily for 14 days. LCMV induced diabetes is prevented in NP and GP transgenic mice treated with anti TNFRSF5 when treated within a defined time window. Splenocytes from these protected mice adoptively transferred disease resistance to LCMV- challenged pre diabetic GP transgenic mice. The cells thatconfer protection express ITGAX5, NK1.1 and DX5. The spleens of anti TNFRSF5 protected mice have an increased population of ITGAX5 expressing cells. When this population of cells is further fractionated into ITGAX5+, DX5+ cells, the recipient mice acquire protection from diabetes. (Homann et al., 2002)
Development
B6.Cg-Tg(Ins2-NP)25-3Olds /MvhJ expresses the lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP) under control of the rat insulin promoter, (Ins2, commonly designated RIP). The transgene was first inserted by Oldstone, et al (1991) into C57BL/6 (H2b) x Balb/WEHI (H2d) F2 oocytes. Line 25-3, maintained by Herrath et al., (1994, 2000) has been backcrossed to C57BL/6 (H2b) for at least 10 generations. In 2003 this strain arrived at The Jackson Laboratory and was backcrossed to C57BL/6J. This strain is maintained +/+ x hemizygote.
| Control | ||
|---|---|---|
| Noncarrier | ||
| 000664 C57BL/6J | (approximate) | |
| Considerations for Choosing Controls | ||
Strains carrying Tg(Ins2-NP)25-3Olds allele
004827 C.Cg-Tg(Ins2-NP)25-3Olds/MvhJ View Strains carrying Tg(Ins2-NP)25-3Olds (1 strain)
Strains carrying other alleles of Ins2
View Strains carrying other alleles of Ins2 (44 strains)
Congenic Nomenclature
View Related Disease (OMIM) Terms
View Mammalian Phenotype Terms
Mammalian Phenotype Terms
assigned by genotype
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Tg(Ins2-NP)25-3Olds/0
involves: BALB/c * C57BL/6
- homeostasis/metabolism phenotype
- decreased circulating insulin level (MGI Ref ID J:81287)
- hypoinsulinemia is exhibited by transgenic mice accompanying increased glucose levels and islet infiltration
- increased circulating glucose level (MGI Ref ID J:81284)
- 3% of transgenic mice develop diabetes when followed for 10-12 months
- 93% of transgenic mice develop diabetes (hyperglycemia of >250 mg/dl glucose and islets infiltrated with mononuclear cells) after being infected with LCMV
- mice are considered diabetic after a blood glucose measure of >300 mg/dl
- endocrine/exocrine gland phenotype
- abnormal islet of Langerhans morphology (MGI Ref ID J:81287)
- pancreata of diabetic transgenic mice show swollen islets with a ground glass appearance
- mononuclear cells begin infiltrating the islets 10 days after viral challenge and are apparent in most transgenic mice after 30 days
- after viral challenge, mononuclear cells infiltrate the islets of transgenic mice bred onto a BALB/c background at 14-21days, while mice bred onto a C57BL/6 background show infiltrates at 21-60 days
- digestive/alimentary phenotype
- abnormal islet of Langerhans morphology (MGI Ref ID J:81287)
- pancreata of diabetic transgenic mice show swollen islets with a ground glass appearance
- mononuclear cells begin infiltrating the islets 10 days after viral challenge and are apparent in most transgenic mice after 30 days
- after viral challenge, mononuclear cells infiltrate the islets of transgenic mice bred onto a BALB/c background at 14-21days, while mice bred onto a C57BL/6 background show infiltrates at 21-60 days
- immune system phenotype
- decreased susceptibility to autoimmune diabetes (MGI Ref ID J:81287)
- depletion of CD8+ lymphocytes with a monoclonal antibody inhibited development of diabetes
- increased susceptibility to autoimmune diabetes (MGI Ref ID J:81287)
- 3% of transgenic mice develop diabetes when followed for 10-12 months
- 93% of transgenic mice develop diabetes (evidenced by hyperglycemia with glucose levels of >300 mg/dl and islets infiltrated with mononuclear cells) after being infected with LCMV
- after viral (LCMV) challenge, transgenic mice bred onto a C57BL/6 background develop diabetes in 3-5 months, whereas transgenic mice bred onto a BALB/c background develop diabetes sooner, at 1-2 months
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Diabetes and Obesity Research
Type 1 Diabetes (IDDM)
Immunology and Inflammation Research
Autoimmunity (Type 1 Diabetes)
Research Tools
Diabetes and Obesity Research
Immunology and Inflammation Research (T Cell Receptor Transgenics)
| Allele Symbol | Tg(Ins2-NP)25-3Olds | ||
|---|---|---|---|
| Allele Name | transgene insertion 25-3, Michael BA Oldstone, MD | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | RIP NP 25-3; RIP-LCMV; RIP-LCMV NP; | ||
| Mutation Made By | Michael Oldstone, The Scripps Research Institute | ||
| Strain of Origin | C57BL/6 x BALB/c | ||
| Expressed Gene | NP, lymphocytic choriomeningitis virus nucleoprotein, viral | ||
| Promoter | Ins2, insulin 2, rat | ||
| Molecular Note | This transgene encodes the nucleoprotein (NP) from Armstrong's clone of the lymphocytic choriomeningitis virus (LCMV) regulated by the rat insulin promoter. Upstream of the NP cDNA are 660 base pairs of regulatory elements in addition to the rat insulin promoter. Downstream of the NP c-DNA is the SV40 small T-antigen intron and late polyadenylation signal. A stable transcript of the expected size was present in the pancreas, as determined by Northern blot analysis. RT-PCR analysis demonstrated that the transcript was expressed in pancreas and thymus, but not the spleen, brain, liver, kidney, heart, muscle or lung. In a T cell recognition assay, LCMV-specific cytotoxic T lymphocytes were shown to migrate specifically to the islets of Langerhans of transgenic mice, but not in control mice. [MGI Ref ID J:81284] [MGI Ref ID J:81287] | ||
Genotyping Protocols
Tg(Ins2-NP)25-3Olds, STD PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
Oldstone MB; Nerenberg M; Southern P; Price J; Lewicki H. 1991. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65(2):319-31. [PubMed: 1901765] [MGI Ref ID J:81284]
von Herrath MG; Dockter J; Oldstone MB. 1994. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1(3):231-42. [PubMed: 7889411] [MGI Ref ID J:81287]
Tg(Ins2-NP)25-3Olds relatedBresson D; Togher L; Rodrigo E; Chen Y; Bluestone JA; Herold KC; von Herrath M. 2006. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 116(5):1371-81. [PubMed: 16628253] [MGI Ref ID J:108962]
Holz A; Bot A; Coon B; Wolfe T; Grusby MJ; von Herrath MG. 1999. Disruption of the STAT4 signaling pathway protects from autoimmune diabetes while retaining antiviral immune competence. J Immunol 163(10):5374-82. [PubMed: 10553062] [MGI Ref ID J:107047]
Holz A; Brett K; Oldstone MB. 2001. Constitutive beta cell expression of IL-12 does not perturb self-tolerance but intensifies established autoimmune diabetes. J Clin Invest 108(12):1749-58. [PubMed: 11748258] [MGI Ref ID J:134571]
Holz A; Dyrberg T; Hagopian W; Homann D; von Herrath M; Oldstone MB. 2000. Neither B lymphocytes nor antibodies directed against self antigens of the islets of Langerhans are required for development of virus-induced autoimmune diabetes. J Immunol 165(10):5945-53. [PubMed: 11067957] [MGI Ref ID J:118383]
Homann D; Holz A; Bot A; Coon B; Wolfe T; Petersen J; Dyrberg TP; Grusby MJ; von Herrath MG. 1999. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 11(4):463-72. [PubMed: 10549628] [MGI Ref ID J:96857]
Homann D; Jahreis A; Wolfe T; Hughes A; Coon B; van Stipdonk MJ; Prilliman KR; Schoenberger SP; von Herrath MG. 2002. CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity 16(3):403-15. [PubMed: 11911825] [MGI Ref ID J:96858]
Hugues S; Mougneau E; Ferlin W; Jeske D; Hofman P; Homann D; Beaudoin L; Schrike C; Von Herrath M; Lehuen A; Glaichenhaus N. 2002. Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells. Immunity 16(2):169-81. [PubMed: 11869679] [MGI Ref ID J:132052]
Martinic MM; Juedes AE; Bresson D; Homann D; Skak K; Huber C; Ling E; Ejrnaes M; Wolfe T; Togher L; Christen U; von Herrath MG. 2007. Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD mice. Diabetes 56(4):1059-68. [PubMed: 17395746] [MGI Ref ID J:122080]
Pauza ME; Nguyen A; Wolfe T; Ho IC; Glimcher LH; von Herrath M; Lo D. 2001. Variable effects of transgenic c-Maf on autoimmune diabetes. Diabetes 50(1):39-46. [PubMed: 11147792] [MGI Ref ID J:133138]
Rhode A; Pauza ME; Barral AM; Rodrigo E; Oldstone MB; von Herrath MG; Christen U. 2005. Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol 175(6):3516-24. [PubMed: 16148094] [MGI Ref ID J:116715]
Von Herrath MG; Coon B; Oldstone MB. 1997. Low-affinity cytotoxic T-lymphocytes require IFN-gamma to clear an acute viral infection. Virology 229(2):349-59. [PubMed: 9126248] [MGI Ref ID J:127684]
von Herrath MG; Dockter J; Oldstone MB. 1994. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1(3):231-42. [PubMed: 7889411] [MGI Ref ID J:81287]
von Herrath MG; Oldstone MB. 1997. Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med 185(3):531-9. [PubMed: 9053453] [MGI Ref ID J:96856]
Colony Maintenance
Diet Information LabDiet® 5K52/5K67
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00 Cryopreserved Embryos Fee $1600.00
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00 Cryopreserved Embryos Fee $2080.00
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
| Control | ||
|---|---|---|
| Noncarrier | ||
| 000664 C57BL/6J | (approximate) | |
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.